Cohance Lifesciences Limited , a prominent player in the pharmaceutical industry, has taken a significant step to bolster its global Contract Development and Manufacturing Organization (CDMO) capabilities. The company has provided a corporate guarantee of $16.50 million to secure a credit facility for its U.S.-based subsidiary, NJ Bio Inc.

Credit Facility Details

Cohance Lifesciences has extended the corporate guarantee to Citibank N.A., enabling NJ Bio Inc. to access a credit facility of $15.00 million. This strategic move is aimed at supporting NJ Bio Inc.'s bioconjugation operations for Antibody-Drug Conjugates (ADCs) in New Jersey, USA.

Terms of the Guarantee

The corporate guarantee comes with the following key terms:

• Guarantee Amount: Up to $16.50 million
• Credit Facility: $15.00 million for NJ Bio Inc.
• Validity: Until June 30, 2028
• Contingent Liability: Capped at $16.50 million for Cohance Lifesciences

Implications for Cohance Lifesciences

The provision of this corporate guarantee creates a contingent liability for Cohance Lifesciences. In the event that NJ Bio Inc. fails to repay the credit facility, Cohance will be obligated to pay the amounts due to Citibank N.A., up to the guaranteed amount.

Strategic Importance

This financial arrangement is expected to strengthen Cohance Lifesciences' global CDMO capabilities, particularly in the specialized area of bioconjugation for Antibody-Drug Conjugates. By supporting its subsidiary's operations in the United States, Cohance is positioning itself to capitalize on opportunities in the advanced pharmaceutical development and manufacturing sector.

Transaction Details

Cohance Lifesciences has confirmed that the transaction was conducted on an arm's length basis, ensuring fairness and transparency. The company has also clarified that there is no involvement or interest from the promoter group in this arrangement.

Regulatory Compliance

The disclosure of this corporate guarantee aligns with Cohance Lifesciences' obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has duly informed both the BSE Limited and the National Stock Exchange of India Limited about this development.

This strategic financial move by Cohance Lifesciences underscores the company's commitment to expanding its global footprint and enhancing its capabilities in the specialized pharmaceutical manufacturing sector.

Cohance Lifesciences , a leading integrated Contract Development and Manufacturing Organization (CDMO), has announced a significant leadership change in its CDMO division. The company has appointed Yann D'Herve as the new Chief Executive Officer of its CDMO business, effective August 1, 2025.

New Leadership for CDMO Division

Mr. D'Herve brings a wealth of experience to Cohance Lifesciences, with a strong track record in senior-level leadership across the pharmaceuticals, healthcare, and specialty chemicals sectors. His appointment comes as part of the company's strategy to accelerate the growth of its CDMO platform.

Extensive Industry Experience

Prior to joining Cohance, D'Herve held several key positions at Evonik, including:

• Senior Vice President and General Manager of Evonik's Healthcare division
• Vice President of Sales and Services
• Various divisional leadership assignments

In his most recent role at Evonik, D'Herve was responsible for 2,600 employees across nine manufacturing sites, with full P&L responsibility, including the company's CDMO business.

Educational Background

Mr. D'Herve's educational qualifications include:

• MBA from Université de Picardie Jules Verne in Amiens
• Master's degree in chemistry from CPE, Lyon, France

Leadership Transition

The appointment of Yann D'Herve coincides with the resignation of Dr. Sudhir Kumar Singh, who previously led the CDMO business as Chief Executive Officer. Dr. Singh will step down from his role effective July 31, 2025, but will remain available to facilitate a seamless transition.

Management Comments

Vivek Sharma, Executive Chairman of Cohance Lifesciences Ltd., expressed enthusiasm about the new appointment:

"We are delighted to welcome Yann to Cohance. His deep experience in leading multifaceted global pharmaceutical services businesses will be of tremendous benefit in accelerating the growth of our CDMO platform."

Yann D'Herve shared his excitement about joining Cohance:

"I am excited to join a growing CDMO with differentiated technologies such as ADCs and oligonucleotides and a strong global asset base. I look forward to working with the Cohance team to support the development and manufacturing of life-saving drugs for our partners."

This strategic appointment underscores Cohance Lifesciences' commitment to strengthening its position in the global CDMO market and enhancing its capabilities in small molecule APIs, Antibody Drug Conjugates (ADCs), and Nucleic Acid Chemistry.